Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib

被引：2
|
作者：
Huang Yi-sheng [1 ]
Huang Biao [2 ]
Wu Yi-long [1 ]
机构：
[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China
[2] Guangdong Gen Hosp, Dept Radiol, Guangzhou 510080, Guangdong, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2011年 / 124卷 / 22期
关键词：
gefitinib; leukoencephalopathy; radiosensitizing; non-small cell lung cancer; RECEPTOR-TYROSINE KINASE; CENTRAL-NERVOUS-SYSTEM; RADIATION; BRAIN; INHIBITOR; NEUROTOXICITY; CHEMOTHERAPY; METHOTREXATE; RADIOTHERAPY; SURVIVAL;
D O I：
10.3760/cma.j.issn.0366-6999.2011.22.043
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The present case is a patient with advanced non-small cell lung cancer (NSCLC) who developed leukoencephalopathy following radiotherapy and gefitinib treatments. There are rarely reports of such incidences because the median survival period of advanced NSCLC is only ten months. The features of leukoencephalopathy in this case were atypical for radiation leukoencephalopathy, so it was suspected that the leukoencephalopathy was associated with gefitinib. Chin Med J 2011;124(22):3834-3837
引用
收藏
页码：3834 / 3837
页数：4
相关论文
共 50 条
  • [21] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    CHEN Min-jiang
    ZHONG Wei
    ZHANG Li
    ZHAO Jing
    LI Long-yun
    WANG Meng-zhao
    中华医学杂志(英文版), 2013, 126 (12) : 2235 - 2241
  • [22] Effectiveness and cost of gefitinib in advanced/metastatic non-small cell lung cancer
    Selvi-Sabater, P.
    Sanchez-Martinez, I.
    Sadyrbaeva-Dolgova, S.
    Portillo-Haro, S.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2020, 42 (01) : 289 - 289
  • [23] The treatment of advanced non-small cell lung cancer
    Spiro, SG
    Silvestri, GA
    CURRENT OPINION IN PULMONARY MEDICINE, 2005, 11 (04) : 287 - 291
  • [24] Treatment of advanced non-small cell lung cancer
    De Petris, L
    Crinò, L
    Scagliotti, GV
    Gridelli, C
    Galetta, D
    Metro, G
    Novello, S
    Maione, P
    Colucci, G
    de Marinis, F
    ANNALS OF ONCOLOGY, 2006, 17 : 36 - 41
  • [25] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [26] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    Song Zheng-bo
    Yu Yong-feng
    Chen Zhi-wei
    Lu Shun
    CHINESE MEDICAL JOURNAL, 2011, 124 (15) : 2279 - 2283
  • [27] Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
    SONG ZhengboYU YongfengCHEN Zhiwei and LU Shun Shanghai Lung Tumor Clinical Medical CenterChest Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China
    中华医学杂志(英文版), 2011, (15) : 2279 - 2283
  • [28] The results of the treatment with gefitinib (Iressa) in 89 patients with advanced non-small cell lung cancer (NSCLC)
    Skrickova, J
    Tomiskova, M
    Svobodnik, A
    Kaplanova, J
    Kadlec, B
    Palkova, I
    Babickova, L
    Stratil, D
    Nebesky, T
    LUNG CANCER, 2005, 49 : S376 - S376
  • [29] Gefitinib A Review of its Use in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer
    Sanford, Mark
    Scott, Lesley J.
    DRUGS, 2009, 69 (16) : 2303 - 2328
  • [30] Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    Brown, T.
    Boland, A.
    Bagust, A.
    Oyee, J.
    Hockenhull, J.
    Dundar, Y.
    Dickson, R.
    Ramani, V. S.
    Proudlove, C.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 71 - 79
12345